THE RUSSIAN PHARMACEUTICAL INDUSTRY IN THE GENERIC SEGMENT: CHALLENGES, TRENDS, AND STRATEGIC PRIORITIES

Abstract

This article is a comprehensive study of the current state and key vectors of the development of the segment of reproduced medicines (generics) in the Russian Federation. The authors conduct a detailed analysis of the dynamics and structure of the domestic generic drug market, demonstrating its steady growth and increasing role in ensuring national drug safety. Particular attention is paid to the impact of sanctions pressure and the geopolitical changes of 2022-2024, which, having caused logistical gaps and the departure of a number of foreign suppliers, simultaneously became a catalyst for accelerated import substitution and localization of production. Based on current analytical data, it is shown that the share of generics occupies a dominant position in the pharmaceutical market. The paper systematically examines the impact of government policy. Key factors that enhance the competitiveness of domestic companies have been identified, including the rapid replacement of imported drugs that have left the market, increased confidence in localized products, and the development of technologically complex forms such as biosimilars. At the same time, the structural limitations of the further development of the industry were identified and analyzed. In the final part, a number of strategic priorities and practical recommendations for the sustainable development of the sector are formulated. The results of the study indicate that the Russian generic drugs industry, overcoming external challenges, demonstrates significant adaptability and potential for further consolidation in the domestic market with the prospect of strengthening its position in the international space.